Pages that link to "Q45976173"
Jump to navigation
Jump to search
The following pages link to Epigenetic modifiers: basic understanding and clinical development. (Q45976173):
Displaying 50 items.
- Epigenomics of leukemia: from mechanisms to therapeutic applications (Q26823403) (← links)
- Customized targeted therapy in Hodgkin lymphoma: hype or hope? (Q27002554) (← links)
- Adoptive cell therapies for glioblastoma (Q27030863) (← links)
- Computational Analysis and Predictive Cheminformatics Modeling of Small Molecule Inhibitors of Epigenetic Modifiers (Q28554035) (← links)
- Clinical Toxicities of Histone Deacetylase Inhibitors (Q31135325) (← links)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. (Q33390876) (← links)
- Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. (Q33393266) (← links)
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma (Q33394324) (← links)
- Romidepsin: in the treatment of T-cell lymphoma (Q33396519) (← links)
- A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors (Q33402619) (← links)
- A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium (Q33409392) (← links)
- Progress toward the clinical application of patient-specific pluripotent stem cells (Q33559694) (← links)
- Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions (Q33705588) (← links)
- Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment (Q33737610) (← links)
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs (Q33829390) (← links)
- Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. (Q34093052) (← links)
- Current limitations and future opportunities for epigenetic therapies. (Q34195077) (← links)
- Pathogenetic mechanisms in gastric cancer (Q34326627) (← links)
- Absence of metallothionein 3 expression in breast cancer is a rare but favorable marker that is under epigenetic control (Q34407376) (← links)
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies (Q34414452) (← links)
- Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity (Q34500688) (← links)
- Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients (Q34575453) (← links)
- New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies (Q34683488) (← links)
- Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer (Q35557022) (← links)
- Artesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine (Q35681469) (← links)
- Romidepsin in the treatment of cutaneous T-cell lymphoma (Q35683831) (← links)
- New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat (Q35703714) (← links)
- Novel therapeutic agents for cutaneous T-Cell lymphoma (Q36161365) (← links)
- Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti (Q36222932) (← links)
- Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin (Q36283075) (← links)
- Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. (Q36923079) (← links)
- Epigenetic changes in pediatric solid tumors: promising new targets (Q36953153) (← links)
- DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer (Q37055333) (← links)
- Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration (Q37182184) (← links)
- Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review). (Q37211663) (← links)
- Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. (Q37254835) (← links)
- CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma (Q37549897) (← links)
- Next generation DNA sequencing and the future of genomic medicine (Q37651413) (← links)
- Pharmacotherapy of myelodysplastic syndromes (Q37756975) (← links)
- Targeted treatment and new agents in peripheral T-cell lymphoma (Q37763879) (← links)
- Histone deacetylase inhibitors in lymphoma (Q37777594) (← links)
- Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies (Q37809875) (← links)
- HLA-G expression in hematologic malignancies (Q37810072) (← links)
- New drug therapies in peripheral T-cell lymphoma (Q37854715) (← links)
- A review of tumour lysis syndrome with targeted therapies and the role of rasburicase (Q37866341) (← links)
- Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions (Q37867482) (← links)
- New therapeutic targets and drugs in non-Hodgkinʼs lymphoma (Q37886574) (← links)
- Romidepsin in the treatment of T-cell lymphoma: profile report (Q37952288) (← links)
- Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma (Q37953956) (← links)
- Small-molecule chromatin-modifying agents: therapeutic applications (Q37961728) (← links)